Author

Elham Ahmadi

Observed name: E. Ahmadi

Institution: McMaster University

Observed institutions: Juravinski Cancer Centre, Hamilton Health Sciences, McMaster University

ORCID: 0000-0003-0472-4615

Observed ORCID: 0000-0003-0472-4615

OpenAlex ID: A5029080896

GDF15 promotes weight loss by enhancing energy expenditure in muscle

2023 · Dongdong Wang, Logan K. Townsend, et al. · Nature · 264

PDF

Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia

2022 · Marisa R. Morrow, Battsetseg Batchuluun, et al. · Cell Metabolism · 196

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

2023 · Amr Ali, Bassem Mekhaeil, et al. · Communications Biology · 64

PDF

ACLY inhibition promotes tumour immunity and suppresses liver cancer

2025 · Jaya Gautam, Jianhan Wu, et al. · Nature · 54

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

2023 · Olga‐Demetra Biziotis, Evangelia Evelyn Tsakiridis, et al. · Molecular Oncology · 41

PDF

Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice

2023 · Eric M. Desjardins, Jianhan Wu, et al. · Cell Reports Medicine · 33

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

2026 · Fiorella Di Pastena, Jaya Gautam, et al. · Cell Metabolism · 22

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

2021 · Evangelia E. Tsakiridis, Lindsay Broadfield, et al. · Translational Oncology · 18

PDF

18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer

2023 · Aruz Mesci, Elham Ahmadi, et al. · Clinical and Translational Radiation Oncology · 8

Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

2024 · Fiorella Di Pastena, Gregory Pond, et al. · Radiation Oncology · 7

PDF

Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance

2023 · Elham Ahmadi, Simon Wang, et al. · International Journal of Molecular Sciences · 6

PDF

GDF15 suppresses liver inflammation independently of weight loss through neuroendocrine glucocorticoid signaling

2026 · Dongdong Wang, Maria Joy Therese Jabile, et al. · Cell Metabolism · 2

Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma

2025 · Evangelia E. Tsakiridis, Elham Ahmadi, et al. · JHEP Reports

PDF

Circulating Growth Differentiation Factor 15 as a Biomarker in Patients with Unresected Locally Advanced Non-Small Cell Lung Cancer Treated with Chemo-Radiotherapy with or without Metformin

2023 · F. Di Pastena, G. Pond, et al. · International Journal of Radiation Oncology*Biology*Physics

PDF

Comparison of pure and PLGA-PAA nano-encapsulated of Hydroxytyrosol and Doxorubicin effects on hTERT and CREB gene expression in HT-29 Colon cancer cell line

2019 · Elham Ahmadi

Works count: 15

Citation count: 715

H-index: 8

I10-index: 8